No Data
No Data
Cathie Wood Goes On Shopping Spree Amid Tech Bloodbath Monday: Loads Up On Tesla, Palantir, Coinbase And These Stocks
Beam Drops 9% on Phase 1/2 Data for Genetic Lung Disease Candidate
Beam Therapeutics Analyst Ratings
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
Jim Cramer: Fiserv Is 'One Of The Greatest Fintechs,' Calls This Tech Company A Meme Stock
Beam Therapeutics Shares Are Trading Lower After the Company Announced a $500 Million Offering.